|
Philippe Lucas
phil@drugsense.org |
|
|
…MAPS
will soon be able
to announce that
an investigation
on the potential
of a novel treatment
for opiate
dependence is
underway in
Canada… |
|
MAPS-Sponsored Ibogaine Observational Case Study Approved
Philippe Lucas
Since February 12, 2005, a MAPS-sponsored research team
working on what is now entitled “Observational Case Series
Study of the Long-Term Efficacy of Ibogaine-Assisted Therapy and
Associated Interventions in Participants with Opiate Addiction Treated
at the Iboga Therapy House”–have exchanged over 200 emails and literally
dozens of versions of this novel research protocol, all with the goal of
getting this study peer-reviewed and approved by a research ethics board.
Way back in February 2005, MAPS
President Rick Doblin contacted me to ask
if I would help steer an ibogaine and
addiction outcome study through the
always-complicated Institutional Review
Board (IRB) process. Since this study was
not associated with a university or
hospital-based researcher, MAPS had to
use a private IRB. Considering that I had
just received approval for a smoked
cannabis and chronic pain double-blind
clinical study from an independent
Canadian review board, Rick asked if I
could help MAPS gain approval for the
ibogaine outcome study taking place at
Iboga Therapy House, located in
Vancouver, British Columbia. Rick had
suggested this IRB to me in the first place
since he had become aware of it during his
search for an IRB that would review
MAPS’ MDMA/PTSD study, which was
finally reviewed and approved by a US
IRB.
As a long-time supporter of MAPS,
I jumped at the chance to work with this
cutting-edge organization. “Sure,” I
answered, “I’ve got a few hours to spare
over the next couple of weeks.” Honestly,
if I had known that 18 months and four
IRB submissions later I would still be
working on this protocol, I undoubtedly
would have answered differently. However,
if I’ve learned anything in the many
years that I’ve been active in drug policyrelated
research and activism, it is patience
and persistence.
And so it now gives me great pleasure
to announce that after months of work
and a number of significant changes to the
original protocol, MAPS has just received
final approval from the IRB to proceed
with this study, which will examine
changes in substance use in 20 consecutive
people seeking ibogaine-based
addiction treatment for opiate dependence
at Iboga Therapy House. While originally
designed as an “outcome study,” the
protocol was later changed to an observational
case-study when the IRB expressed
concerns that the initial design was too
close to a clinical trial (which has a much
stricter approval process, and was never
the intention of the research team anyhow).
The Principal Investigator is none
other than Rick Doblin, Ph.D., and he’ll be
aided by Dr. Ken Alper and Leah Martin,
with data analysis to be conducted by
MAPS Research Associate Ilsa Jerome.
Now that all of the IRB’s concerns
have been successfully addressed, MAPS
will soon be able to announce that an
investigation on the potential of a novel
treatment for opiate dependence is
underway in Canada, and I can finally get
some well-deserved rest … at least until
the next time Rick calls me up!
Philippe Lucas is Founder/Director of
the Vancouver Island Compassion Society,
Research Fellow at the Center for Addiction
Research of British Columbia, and the Director
of Communications for DrugSense. |